David Denton - Pfizer Chief VP

PFE Stock  USD 25.64  0.51  2.03%   

Insider

David Denton is Chief VP of Pfizer Inc
Age 59
Address 66 Hudson Boulevard East, New York, NY, United States, 10001-2192
Phone212 733 2323
Webhttps://www.pfizer.com

David Denton Latest Insider Activity

Tracking and analyzing the buying and selling activities of David Denton against Pfizer stock is an integral part of due diligence when investing in Pfizer. David Denton insider activity provides valuable insight into whether Pfizer is net buyers or sellers over its current business cycle. Note, Pfizer insiders must abide by specific rules, including filing SEC forms every time they buy or sell Pfizer'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Pfizer Management Efficiency

The company has Return on Asset of 0.0331 % which means that on every $100 spent on assets, it made $0.0331 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0454 %, implying that it generated $0.0454 on every 100 dollars invested. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to 0.02. In addition to that, Return On Capital Employed is expected to decline to 0.02. At present, Pfizer's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 9.7 B, whereas Total Current Assets are forecasted to decline to about 32.2 B.
Pfizer Inc has 75.04 B in debt with debt to equity (D/E) ratio of 0.4, which is OK given its current industry classification. Pfizer Inc has a current ratio of 1.56, which is typical for the industry and considered as normal. Note however, debt could still be an excellent tool for Pfizer to invest in growth at high rates of return.

Similar Executives

Showing other executives

INSIDER Age

Mathai MammenJohnson Johnson
53
Stuart MathewsGold Fields Ltd
59
Dean LiMerck Company
58
Tim HansenDorian LPG
55
A WashingtonJohnson Johnson
70
Styliani DimarakiAegean Airlines SA
N/A
Anre WeststrateGold Fields Ltd
55
Wanda FearingCinemark Holdings
60
Jennifer MauerMerck Company
N/A
Michael FlemingMerck Company
61
Aliza ScottFormFactor
N/A
R BardienGold Fields Ltd
N/A
Vanessa BroadhurstJohnson Johnson
52
Dirk BrinckmanJohnson Johnson
N/A
Damian WardleCinemark Holdings
N/A
Chunyi LeongFormFactor
49
Rosh BardienGold Fields Ltd
48
Robert SelleyFormFactor
55
Robert DeckerJohnson Johnson
52
BCom BComGold Fields Ltd
55
Pehlevanoudis ZisisAegean Airlines SA
N/A
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 79000 people. Pfizer Inc (PFE) is traded on New York Stock Exchange in USA. It is located in 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 and employs 88,000 people. Pfizer is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Pfizer Inc Leadership Team

Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Young, Group President - Pfizer Innovative Health and Angela Hwang
Jennifer Damico, Senior Vice President Principal Accounting Officer, Controller
Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
Douglas Lankler, Executive Vice President General Counsel
Dawn Rogers, Chief Human Resource Officer, Executive Vice President
Helen Hobbs, Independent Director
Shantanu Narayen, Lead Independent Director
James Smith, Independent Director
Christopher CFA, VP Officer
Michael Mcdermott, Executive Vice President Chief Global Supply Officer
Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and Medical
Susan DesmondHellmann, Independent Director
Francesca DeMartino, Chief Officer
Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital Officer
Gordon Loh, Senior Vice President Corporate Audit
Wyllie Cornwell, Independent Director
Suzanne Johnson, Independent Director
David Denton, Chief VP
Alexander Mackenzie, Executive Vice President Chief Development Officer
Aamir Malik, Executive Vice President Chief Business Innovation Officer
Christopher Stevo, Senior Vice President and Chief Investor Relations Officer
DVM DVM, Chairman CEO
William Gray, Independent Director
Sally Susman, Chief Corporate Affairs Officer, Executive Vice President
Susan Hockfield, Independent Director
William Carapezzi, Executive Vice President - Global Business Services and Transformation
Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice President
Mikael MD, Chief Development
Albert DVM, Chairman CEO
Dan Littman, Independent Director
Payal Becher, Chief VP
James Kilts, Independent Director
James Quincey, Independent Director
Andreas Panayiotou, Global Officer
Joseph Echevarria, Independent Director
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business
Payal Sahni, Executive Vice President, Chief People Experience Officer
Angela Hwang, Group President - Pfizer Biopharmaceuticals Group
Mike Mcdermott, Executive Vice President Chief Global Supply Officer
Scott Gottlieb, Independent Director
Ronald Blaylock, Independent Director

Pfizer Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.98)
Dividend Share
1.67
Earnings Share
0.75
Revenue Per Share
10.493
Quarterly Revenue Growth
0.312
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.